NASDAQ:CTSO - Cytosorbents Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.33
  • Forecasted Upside: 128.70 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.83
▼ -0.21 (-3.48%)

This chart shows the closing price for CTSO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytosorbents Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTSO

Analyst Price Target is $13.33
▲ +128.70% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cytosorbents in the last 3 months. The average price target is $13.33, with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 128.70% upside from the last price of $5.83.

This chart shows the closing price for CTSO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Cytosorbents. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021B. RileyInitiated CoverageBuyHigh
10/13/2021CowenLower Price TargetOutperform$14.00 ➝ $10.00High
10/10/2021SVB LeerinkReiterated RatingBuyLow
8/4/2021HC WainwrightReiterated RatingBuy$13.00High
1/4/2021B. RileyBoost Price TargetOutperform ➝ Buy$16.00 ➝ $17.00N/A
9/17/2020Jefferies Financial GroupInitiated CoverageBuy$15.00Medium
9/1/2020SVB LeerinkInitiated CoverageOutperform$15.00Medium
7/23/2020B. RileyReiterated RatingBuyLow
6/12/2020B. RileyInitiated CoverageBuy$16.00Medium
5/7/2020Maxim GroupInitiated CoverageBuy$14.00Low
5/6/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
5/6/2020B. RileyBoost Price TargetBuy$12.00 ➝ $16.00High
4/16/2020HC WainwrightReiterated RatingBuy$13.00Low
3/26/2020Maxim GroupReiterated RatingBuy$8.00High
3/9/2020Dawson JamesReiterated RatingBuy$15.00 ➝ $17.00High
3/6/2020HC WainwrightReiterated RatingBuy$13.00Low
11/27/2019B. RileyReiterated RatingBuy$12.00Low
11/26/2019HC WainwrightReiterated RatingBuy$13.00High
11/25/2019Maxim GroupReiterated RatingBuy$8.00High
10/21/2019B. RileySet Price TargetBuy$10.00Low
8/7/2019HC WainwrightReiterated RatingBuyHigh
8/7/2019Maxim GroupSet Price TargetBuy$14.00High
7/19/2019B. RileySet Price TargetBuy$12.00N/A
5/8/2019Maxim GroupSet Price TargetBuy$14.00High
3/8/2019Maxim GroupReiterated RatingBuy$18.00High
3/8/2019HC WainwrightReiterated RatingBuy$15.00High
1/14/2019HC WainwrightSet Price TargetBuy$15.00High
12/20/2018Maxim GroupSet Price TargetBuy$10.00Low
11/7/2018HC WainwrightSet Price TargetBuy$15.00High
9/4/2018Maxim GroupReiterated RatingBuy$18.00Low
8/3/2018CowenReiterated RatingBuy$15.00High
5/15/2018Maxim GroupSet Price TargetBuy$13.00High
5/9/2018Maxim GroupSet Price TargetBuy$12.00High
5/9/2018HC WainwrightReiterated RatingBuy$14.00High
4/24/2018Maxim GroupSet Price TargetBuy$12.00High
3/9/2018HC WainwrightSet Price TargetBuy$14.00Medium
3/9/2018Maxim GroupSet Price TargetBuy$12.00Medium
3/8/2018CowenSet Price TargetBuy$9.00Medium
1/25/2018B. RileyReiterated RatingBuy$11.25Low
1/9/2018HC WainwrightReiterated RatingBuy$14.00Medium
1/8/2018Maxim GroupSet Price TargetBuy$12.00N/A
12/22/2017B. RileySet Price TargetBuy$11.00High
12/21/2017Maxim GroupSet Price TargetBuy$12.00High
12/11/2017Maxim GroupSet Price TargetBuy$12.00Low
11/21/2017HC WainwrightReiterated RatingBuy$13.00N/A
11/10/2017B. RileyReiterated RatingBuy$11.25N/A
11/10/2017Maxim GroupReiterated RatingBuy$12.00N/A
10/19/2017Maxim GroupSet Price TargetBuy$12.00N/A
9/26/2017HC WainwrightReiterated RatingBuy$13.00Low
8/12/2017B. RileyReiterated RatingBuy$11.25Low
8/8/2017HC WainwrightSet Price TargetBuy$13.00High
8/8/2017Maxim GroupBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.00High
8/7/2017B. RileyReiterated RatingBuy$11.25Medium
8/2/2017B. RileyReiterated RatingBuy$11.25Medium
7/25/2017AegisReiterated RatingBuy$9.00High
7/17/2017Maxim GroupSet Price TargetBuy$10.00Medium
7/5/2017Maxim GroupReiterated RatingBuy$10.00Low
6/7/2017CowenInitiated CoverageOutperform$7.00High
5/22/2017Maxim GroupSet Price TargetBuy$10.00Medium
5/15/2017B. RileyReiterated RatingBuy$11.25Low
5/10/2017B. RileyReiterated RatingBuy$11.25Low
5/9/2017AegisReiterated RatingBuy$9.00High
5/6/2017Maxim GroupSet Price TargetBuy$10.00High
5/5/2017B. RileyReiterated RatingBuy$11.25Medium
4/25/2017Maxim GroupReiterated RatingBuy$10.00High
4/19/2017Maxim GroupReiterated RatingBuy$10.00High
4/11/2017B. RileyReiterated RatingBuy$11.25Low
4/5/2017B. RileyReiterated RatingBuy$11.25Low
3/22/2017Maxim GroupReiterated RatingBuy$10.00Medium
3/16/2017Maxim GroupReiterated RatingBuy ➝ BuyHigh
3/11/2017B. RileyReiterated RatingBuy$11.25N/A
3/7/2017AegisReiterated RatingBuyLow
3/6/2017B. RileyReiterated RatingBuy$11.25N/A
3/6/2017HC WainwrightBoost Price TargetBuy$11.50 ➝ $13.00N/A
3/4/2017Maxim GroupSet Price TargetBuy$10.00N/A
3/1/2017B. RileyReiterated RatingBuy$11.25N/A
1/23/2017Maxim GroupBoost Price TargetBuy$8.00 ➝ $10.00N/A
12/7/2016Maxim GroupSet Price TargetBuy$8.00N/A
12/1/2016Maxim GroupSet Price TargetBuy$8.00N/A
11/22/2016Maxim GroupSet Price TargetBuy$8.00N/A
11/14/2016B. RileyReiterated RatingBuy$11.25N/A
11/9/2016B. RileyReiterated RatingBuy$11.25N/A
11/8/2016HC WainwrightReiterated RatingBuyN/A
11/4/2016B. RileyReiterated RatingBuy$11.25N/A
10/26/2016AegisInitiated CoverageBuy$20.00N/A
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/24/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
9/23/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
10/23/2021

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Cytosorbents logo
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Read More

Today's Range

Now: $5.83
Low: $5.79
High: $6.02

50 Day Range

MA: $8.14
Low: $5.85
High: $9.71

52 Week Range

Now: $5.83
Low: $5.79
High: $11.68

Volume

208,148 shs

Average Volume

292,733 shs

Market Capitalization

$252.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytosorbents?

The following Wall Street sell-side analysts have issued research reports on Cytosorbents in the last year: B. Riley, Cowen Inc, HC Wainwright, and SVB Leerink LLC.
View the latest analyst ratings for CTSO.

What is the current price target for Cytosorbents?

3 Wall Street analysts have set twelve-month price targets for Cytosorbents in the last year. Their average twelve-month price target is $13.33, suggesting a possible upside of 128.7%. B. Riley has the highest price target set, predicting CTSO will reach $17.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $10.00 for Cytosorbents in the next year.
View the latest price targets for CTSO.

What is the current consensus analyst rating for Cytosorbents?

Cytosorbents currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTSO will outperform the market and that investors should add to their positions of Cytosorbents.
View the latest ratings for CTSO.

How do I contact Cytosorbents' investor relations team?

Cytosorbents' physical mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company's listed phone number is (732) 329-8885 and its investor relations email address is [email protected] The official website for Cytosorbents is www.cytosorbents.com.